Request Demo
Last update 24 May 2025
Estriol
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (16α,17β)-estra-1,3,5(10)-triene-3,16,17-triol, 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol, 16-alpha-Hydroxyestradiol + [18] |
Target |
Action agonists |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (18 Nov 1960), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H24O3 |
InChIKeyPROQIPRRNZUXQM-ZXXIGWHRSA-N |
CAS Registry50-27-1 |
Related
36
Clinical Trials associated with EstriolNCT06873971
Effects of Erbium-Yag Laser in Women With Genitourinary Syndrome of Menopause Undergoing Estrogen Therapy: Randomized, Controlled, Double-Blind Study
ChiCTR2500095868
Benefit analysis of estriol suppository for colposcopy in postmenopausal women
NCT06391372
Effect of Local Estriol Treatment Before Vaginal Repair Surgery on Vaginal Tissues and Early Postoperative Pelvic Floor Functions
100 Clinical Results associated with Estriol
Login to view more data
100 Translational Medicine associated with Estriol
Login to view more data
100 Patents (Medical) associated with Estriol
Login to view more data
10,729
Literatures (Medical) associated with Estriol01 Aug 2025WATER RESEARCH
Biodegradation pathways and mechanisms of 17α-ethynylestradiol via functional enzymes in the freshwater microalga Scenedesmus quadricauda
Article
Author: Hua, Feng ; Xu, Wenju ; Liu, Xiaojuan ; Wang, Zhen ; Wang, Yuwen ; Meador, James P ; Zhou, Guang-Jie ; Wu, Xiaomin ; Liu, Wenhua
17α-ethynylestradiol (EE2) is a potent synthetic hormone exhibiting very high estrogenic activity and low rates of biodegradation. The removal capabilities of EE2 by bacteria, fungi and algal-bacterial symbiotic systems have attracted considerable attention recently. Specifically, algal biodegradation has been explored recently; however, the pathway and mechanisms of EE2 degradation have remained largely unknown. Therefore, we investigated the pathways and mechanisms by which EE2 is degraded by the freshwater microalga Scenedesmus quadricauda. After exposure for 10.5 d, the algal species was able to metabolize 58 % of a 15 mg/L solution of EE2, with the highest removal rate of 13 % occurring at 1.5 d An Ultra Performance Liquid Chromatography-Q-Exactive Orbitrap Mass Spectrometry was used innovatively to identify the biodegradation products of EE2 through non-target screening, followed by the verification of standard compounds. Transcriptomic analysis and molecular docking analysis revealed several degradation pathways and mechanisms by this algal species. One pathway was the demethylation of EE2 to estradiol (E2) by short-chain dehydrogenase/reductase. Subsequently, we also observed interconversion of estrone (E1) and E2 by 17β-hydroxysteroid dehydrogenase through hydroxylation or ketonization, hydroxylation of E1 to 16α-hydroxyestrone (16-OH E1) by cytochrome P450 and flavin-containing monooxygenase. A second pathway was methoxylation of E2 to estradiol acetate by catechol O-methyltransferase. As a result, the ethynyl group was degraded to hydroxy, ketone and methoxyl groups, which promotes EE2 degradation. Considering that EE2 pollution could result in adverse effects for aquatic organisms, the results of this study provide insights and a comprehensive approach for practical and effective bioremediation of EE2 contamination in aquatic ecosystems.
01 Jul 2025SEPARATION AND PURIFICATION TECHNOLOGY
Efficient and highly selective deep removal of hydrophobic organic compounds from leachate by polyamide microplastics
Author: Tang, Shuai ; Zheng, Yuxin ; Cao, Chengjin ; Ma, Shengjia ; Zhao, Yaping ; Xu, Bingqian
High levels of hydrophobic organic compounds (HOCs) have been detected in the landfill leachates.However, due to the complex leachate composition with high organic content, removing HOCs has proven to be challenging.Herein, we focused on the efficiency and selectivity of polyamide microplastics (PA MPs) in adsorbing HOCs from real landfill leachate.Using bisphenol A (BPA) as a model HOC, PA MPs highly selectively removed 100 % of trace concentrations (1-500 μg·L-1) of BPA from leachate containing 827 mg·L-1 of dissolved organic carbon (the concentration ratio of DOC/pollutant was up to 8.27 x 105).D. functional theory calculations confirmed that the selectivity of PA MPs in leachate was primarily related to hydrogen bonding.Various environmental factors (solution pH, anions, natural organic matters, hydrophilic pollutants, dissolved organic carbon, and the high chroma of leachates) had little effects on the adsorption of BPA.Furthermore, PA MPs were completely removed by magnetic zero-valent iron loaded with porous carbon through simple shaking.This study demonstrates PA MP′s effectiveness in selectively removing trace HOCs from leachate and showed significant industrial potential for wastewater treatment.
01 Jul 2025JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
Author: Wang, Zijian ; Meng, Qingling ; Wen, Zhao ; Sun, Kaicheng ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2
News (Medical) associated with Estriol
100 Deals associated with Estriol
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infertility | China | - | 01 Jan 2000 |
| Vulvovaginal atrophy | United Kingdom | 20 Aug 1982 | |
| Osteoporosis | Japan | 28 Dec 1981 | |
| Female Urogenital Diseases | Japan | 27 Sep 1972 | |
| Menopausal symptoms | Japan | 18 Nov 1960 | |
| Uterine Cervical Erosion | Japan | 18 Nov 1960 | |
| Uterine Cervicitis | Japan | 18 Nov 1960 | |
| Vaginitis | Japan | 18 Nov 1960 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| vaginal mucosa dry | Phase 2 | Czechia | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | Hungary | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | Italy | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | Spain | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | Sweden | 01 Oct 2016 | |
| Atrophic Vaginitis | Phase 2 | Spain | 16 Oct 2015 | |
| Atrophic Vaginitis | Phase 2 | Sweden | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | Spain | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | Sweden | 16 Oct 2015 | |
| Multiple Sclerosis | Phase 2 | United States | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | c-myc expression | 33 | Combined oral hormonal contraceptive + Placebo | ljtryejafj(eojkxlfrko) = ysxdsayvpo fcmqdpacmj (plitlsfjds, 10.65) | - | 01 Mar 2023 | |
Combined oral hormonal contraceptive + Estriol | ljtryejafj(eojkxlfrko) = pitwzkbjrf fcmqdpacmj (plitlsfjds, 9.88) | ||||||
Phase 3 | 167 | (0.005% Estriol Group) | lgnwfznpep(xcypvmffgk) = ekiqsgrbwc upiwepshri (shxxtplcxq, 23.33) View more | - | 11 Dec 2020 | ||
Placebo (Placebo Group) | lgnwfznpep(xcypvmffgk) = lhpretbfmx upiwepshri (shxxtplcxq, 16.48) View more | ||||||
Phase 2 | 283 | (Estriol 0.005%) | bkoeozbzpa = mlqmdfesfx txhuqymysc (oxmoelzptm, gpvqtfrslt - nydjmtgewp) View more | - | 25 Sep 2019 | ||
(Estriol 0.002%) | bkoeozbzpa = wzmzgcjwuu txhuqymysc (oxmoelzptm, qfpesdnyux - ghjgpdqpxm) View more | ||||||
Phase 2 | 61 | (0.005% Estriol Vaginal Gel) | ydrkztmezf(fklzpperdq) = phactpsflo uciiuubnna (smjerilgru, isosykcebw - ifhhcgabev) View more | - | 05 Aug 2019 | ||
Placebo (Placebo Vaginal Gel) | ydrkztmezf(fklzpperdq) = desntxtuqc uciiuubnna (smjerilgru, qbbpuajkld - eoubkmxuwc) View more | ||||||
Phase 2 | 123 | (Bevacizumab Spray) | grkcmelglg(amgrcqpopy) = zvigtivmkt qiywjxwggk (qiuzpvxljk, uungclkhok - kfogqkbitz) View more | - | 19 Oct 2018 | ||
(Estriol Spray) | grkcmelglg(amgrcqpopy) = pejvcpwnbq qiywjxwggk (qiuzpvxljk, xyuvysfcbv - imvplfgwve) View more | ||||||
Phase 2 | - | 21 | (Study Arm 1) | bmqvhxvhus(llahmbvigi) = odhepsvilz yyklzcrrsr (zakvjsvntm, 12.5) View more | - | 16 May 2018 | |
(Study Arm 2) | bmqvhxvhus(llahmbvigi) = tscdfwcckb yyklzcrrsr (zakvjsvntm, 0) View more | ||||||
Phase 2 | 70 | Estriol vaginal gel | txwghdonio(tqttxvxujt) = One serious adverse event emerged before the patient initiated treatment zawivwssph (nawqdgdhej ) View more | Positive | 15 Feb 2018 | ||
Placebo gel | |||||||
Phase 2 | 158 | faksmsmjos(meinyswjoo) = rvqrikgktf zqcnlkuqdq (lrcsdiwstn, iansohojgm - wvltseytak) View more | - | 16 Jun 2016 | |||
Placebo+Copaxone (Placebo Capsules Plus Copaxone Injections) | faksmsmjos(meinyswjoo) = basjqdqswd zqcnlkuqdq (lrcsdiwstn, qloxtqhcwh - mqzlqisjkt) View more | ||||||
Phase 2 | 164 | wicreaoruu(jkbubhhuic) = glawyihmqj wtqweqckrm (xoqsdwltem, 0.17 - 0.37) View more | Positive | 01 Jan 2016 | |||
Placebo | wicreaoruu(jkbubhhuic) = qptdndkaot wtqweqckrm (xoqsdwltem, 0.25 - 0.53) View more | ||||||
Not Applicable | - | Vaginal estriol-lactobacilli combination | xeeqxxqtmg(wztikrjkpi) = wiwjqxzgck qhjewpqpke (vqikmgwnge ) View more | - | 04 Mar 2015 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free